Tyrosine kinase inhibitors (TKIs) targeting HER2, such as tucatinib, lapatinib, and neratinib, were also incorporated into the therapeutic arsenal of patients with metastatic BC[9]. This evidence concerns the gene ERBB2 and breast cancer.